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sustained virologic response (SVR) rates with the currently ap-
proved interferon-based therapies, these therapies are limited
by the on-treatment side effects and by the relatively inferior
response in patients with HCV genotype 1 infection. Several host
and viral factors have been implicated to inﬂuence the disease
progression and the treatment response in chronic hepatitis
C (CHC) patients, and efforts to modify these factors to the
optimize the therapeutic response are ungently needed.
Recently, host metabolic factors, such as diabetes mellitus (DM),
insulin resistance (IR), hepatic steatosis, and impaired lipid
metabolism have been found to closely associated with HCV
infection. Ample clinical evidence indicate that deranged lipid
proﬁles and hepatic steatosis correlate with HCV infection, sug-
gesting their potential roles of predicting therapeutic responses.
Furthermore, it has been demonstrated in vitro that the lipid
rafts, mainly composed of cholesterol and sphingolipid, and the
lipid droplet, an organelle for storing neutral lipids, play the cru-
tial roles of producing infectious viruses. While HCV genotypes 3
virus may directly cause hepati steatosis, the association of viral
loads in HCV genotype 1 or 2 virues, the mainly types in infected
individuals in the world, with the lipid proﬁles still remains
elusive. The search of the association between lipid proﬁles and
the HCV genotypic differences is therefore important.
A recent study recruting 531 patients with either HCV genotype
1 or 2 infection showed that high serum triglyceride, totoal
cholesterol and low-density lipoprotein (LDL) correlated with
high HCV RNA levels. In patients with low body mass index (BMI),
high modeal assessment of insulin resistance index (HOMA-IR)
and total cholesterol levels were associated with high HCV viral
load. After stratiﬁcation by HCV genotypes, lipid proﬁles were
highly associated with HCV viral load in genotype 2, rather than
genotype 1 patients. The study indicated that differed mecha-
nisms of deranged lipid proﬁles between HCV genotype 1 and
2 viruses. Because the casual relationship of the viral load and
the lipid proﬁles are still to be determined, manipulation of the
lipid proﬁles aiming in improving the anti-HCV therapy deserves
further studies.
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Patrick C.Y. Woo*. Department of Microbiology, The University
of Hong Kong, Hong Kong, China
Despite extensive investigations, a microbiological cause cannot
be found in about half of the patients with infectious disease.
Throughout the years, scientists have spent tremendous efforts
in looking for microorganisms associated with these “unexplained
infectious disease syndromes”. In 2001, we discovered Laribac-
ter hongkongensis gen. nov. sp. nov., a facultative anaerobic,
Gram-negative, S-shaped, urease-positive rod of the Neisseri-
aceae family, from blood and empyema thoracis of a patient with
alcoholic cirrhosis. During the past eight years, we have docu-
mented that L. hongkongensis was associated with community
acquired gastroenteritis and traveler’s diarrhea and cases were
found globally in patients who resided in or had recent travel
histories to countries in Asia, Europe, America and Africa. We
have found that freshwater ﬁsh is the reservoir and it was also
found in Chinese tiger frogs and drinking water reservoirs. Due
to the potential of its clinical importance and related ecology,
important phenotypic characteristics and phylogenetic position,
and the availability of genetic manipulation systems for down-
stream experiments, we sequenced the complete genome of L.
hongkongensis, with the aim of achieving better understanding
of its biology, mechanism of adaptation to different hosts, and
virulence mechanisms. The complete genome sequence of L.
hongkongensis consists of a 3,169-kb chromosome with G+C con-
tent of 62.35%. Genome analysis reveals different mechanisms
potentially important for its adaptation to diverse habitats of hu-
man and freshwater ﬁsh intestines and freshwater environments.
The gene contents suggest that amino acids and fatty acids can
be used as carbon sources. The extensive variety of transporters
including multidrug efﬂux and heavy metal transporters, as well
as genes involved in chemotaxis may enable L. hongkongensis
to survive in different environmental niches. Genes encoding
urease, bile salts efﬂux pump, adhesin, catalase, superoxide dis-
mutase and other putative virulence factors, such as hemolysins,
RTX toxins, patatin-like proteins, phospholipase A1 and colla-
genases, are present. Proteomes of L. hongkongensis cultured
at 37°C and 20°C showed differential gene expression, includ-
ing two homologous copies of argB, argB-20 and argB-37, that
encode two isoenzymes of N-acetyl-L-glutamate kinase (NAGK),
NAGK-20 and NAGK-37, in the arginine biosynthesis pathway.
NAGK-20 showed higher expression at 20°C whereas NAGK-37
showed higher expression at 37°C. NAGK-20 also had a lower
optimal temperature for enzymatic activities and was inhibited
by arginine probably as negative feedback control. Similar du-
plicated copies of argB are also observed in bacteria from hot
springs, including Thermus thermophilus, Deinococcus geother-
malis, Deinococcus radiodurans and Roseiﬂexus castenholzii,
suggesting that similar mechanisms for temperature adaptation
may be employed by other bacteria.
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Increasing antimicrobial resistance brings difﬁculties for selec-
tion of effective antimicrobial regimens in the treatment of
bacterial infections. Antimicrobial resistance trends and ther-
apeutic options will be discussed for the following highly an-
timicrobial resistant gram-negative bacilli: ESBL-producing Es-
cherichia coli and Klebsiella pneumoniae, and multiple-resistant
Pseudomonas aeruginosa and Acinetobacter baumannii. ESBLs-
producing strains of E. coli and K. pneumoniae have been
increasing and currently approximately half of the strains pro-
duce ESBLs in China. Carbapenems produce the best outcomes
in the treatment of ESBLs infections. In vitro ESBL-producing
organisms vary in their susceptibility to other antimicrobials.
The susceptibility rates of ESBL-producing strains are relatively
high to β-lactamase inhibitor combinations such as cefoperazone-
sulbactam and piperacillin-tazobactam, which might be used in
the treatment of such infections in high dosage. The isolation
of P. aeruginosa and A. baumannii, the most common pathogens
in ventilator-associated pneumoniae (VAP), has been increas-
ing in clinical specimens. Both P. aeruginosa and A. baumannii
are non-fermenters, which are highly resistant to antimicrobial
agents. According to a bacterial surveillance program, CHINET,
in China, the resistance rates of P. aeruginosa clinical strains
to ceftazidime, piperacillin-tazobactam, imipenem, meropenem
and ciproﬂoxacin were from 21% to 30% in 2008, while the
resistance rates were relatively lower to amikacin, cefepime
and cefoperazone-sulbactam with resistance rates from 15% to
18%. Acinetobacter spp. was more resistant to most antimicro-
bials than did P. aeruginosa. The choice of antimicrobial agents
should be based on the in-vitro susceptibility results. For severe
infections, combination therapy is recommended as following:
an active β-lactam combined with an aminoglycoside or with a
quinolone such as ciproﬂoxacin or levoﬂoxacin. A. baumannii is
highly susceptible to doxycycline or minocycline, but the clinical
experience is limited. Colistin has emerged again as a thera-
peutic option for pandrug resistant (PDR) P. aeruginosa and A.
Concurrent Sessions S9
baumannii infections. Tigecycline, a glycylcycline antibiotic, is
active against A. baumannii and it has been used in the treatment
of VAP caused by this pathogen in some countries or regions.
CS5-03 MDR, XDR, and PDR Gram-Negative Bacterial
Infections: An Evolving Global Public Health
Problem
Matthew E. Falagas*. Director, Alfa Institute of Biomedical
Sciences, Athens, Greece; Adjunct Associate Professor of
Medicine, Tufts University School of Medicine, Boston,
Massachusetts, USA
The advanced antimicrobial resistance of Gram-negative bacilli
(mainly A. baumannii, Pseudomonas aeruginosa, and extended
spectrum beta-lactamase producing Enterobacteriaceae, includ-
ing Klebsiella pneumoniae) has become a global public health
threat. The intrinsic or acquired antimicrobial resistance in these
clinically important pathogens is mediated with various mech-
anisms (production of beta-lactamases and/or enzymes inacti-
vating aminoglycosides, efﬂux pumps, lower permeability of the
outer membrane, mutations in antibiotic targets, etc.). Broad-
spectrum beta-lactam antibiotics have been considered the ﬁrst
choice for the treatment of patients with multiple drug resistant
A. baumannii and Pseudomonas aeruginosa infections. However,
the worrisome pattern of increasing antimicrobial resistance of
these pathogens has led to re-evaluation and use of intravenous
and aerosolized polymyxins (mainly colistin) in various parts of
the world. In addition, various agents with novel mechanisms
of antibacterial action have been investigated, although there
are no available clinical data regarding their effectiveness and
safety. Also, the developments in the advancing pattern of
antimicrobial resistance of Gram-negative bacilli has been asso-
ciated with the use of a diversity of deﬁnitions of multiple drug
resistant (MDR), extensively drug resistant (XDR), and pandrug
resistant (PDR) pathogens on which we have commented (Falagas
ME et al. Clin Microbiol Infect 2005;11:1049, J Med Microbiol
2006;55:1619, and Clin Infect Dis 2008;46:1121). Considering
various issues, the terms “pandrug resistance”, “extensive drug
resistance”, and “multidrug resistance” should designate resis-
tance of a pathogen to all, resistance to all but 1 or 2, and
resistance to at least three, respectively, classes of antimicrobial
agents, among those that are available at the time of use of
the deﬁnition in most parts of the world and are regarded as
potentially effective against the respective pathogen.
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Background and aims: Leishmaniasis is caused by parasitic proto-
zoa of the genus Leishmania; humans are infected via the bite of
phlebotomine sandﬂies. It is prevalent in 88 countries, affecting
an estimated 12 million people with approximately 2 million new
cases per year, 500,000 of which are Visceral Leishmaniasis (VL)
and l,500,000 Cutaneous form (CL), representing a signiﬁcant
rank among communicable diseases. Moreover, Leishmania/HIV
coinfection has been reported in 35 countries worldwide. There
are four main types of the disease: In CL, skin ulcers usually
form on exposed areas, which usually heal within a few months,
leaving scars. Diffuse cutaneous leishmaniasis (DCL) produces
disseminated and chronic skin lesions resembling those of lep-
romatous leprosy which is difﬁcult to treat. In muco-cutaneous
form (MCL), the lesions can partially or totally destroy the
mucous membranes of nose, mouth and throat cavities and sur-
rounding tissues. VL is characterized by high fever, substantial
weight loss, swelling of the spleen/liver and anaemia with high
fatality rate within two years. The aim of this study is to analyze
current situation of leishmaniasis as a neglected tropical disease
in the world, Eastern Mediterranean Region and Iran.
Methods: The global burden of leishmaniasis was discussed with
respect to ﬁnancial and political impacts; relation to poverty;
stigma of pathologies; effective implemented tools, available re-
sources and lack of input from pharmaceutical and biotechnology
companies to develop new drugs and vaccines. Criteria by which
different types of leishmaniasis could be prioritized as target
disease were set. These criteria included: incidence, prevalence
and severity of the disease, lack of response to available drugs;
the impact of treatment of individuals on control of transmission
and lack of other major parties involved in drug development.
There are no adequately effective therapies, but some encour-
aging results have been obtained with immuno-modulators plus
antimonials and herbal extracts. Immunogenicity clinical trials
are currently ongoing with whole killed Leishmania parasites,
second generation and DNA vaccines.
Results: According to the current data, the overall inci-
dence/prevalence rates, and social/ﬁnancial burdens of leish-
maniasis are high. The analysis of published trials indicates that
the available drugs are inadequate; the quality of most trials is
poor and requires both improvement and standardization. The
mechanism for controlling Leishmania infection to reach a stable
self healing process is a balanced immune response, however
immune stimulation during chemotherapy can enhance cure.
Conclusions: Neglected tropical diseases are a symptom of
poverty and disadvantage. With little political voice, neglected
leishmaniasis has a low proﬁle and status in public health pri-
orities. In addition, the problem of Leishmania/HIV coinfection
is spreading to the countries that are the world’s major foci of
leishmaniasis. There is an urgent need for new treatments for all
leishmaniasis. Immuno-chemotherapy with therapeutic vaccines
or immunomodulators has a strong potential to make an impact
as a new therapy with shortening duration and reducing dose
of drug treatment and preventing resistance. There is also a
need for safe, affordable and efﬁcacious novel chemotherapeu-
tics. The quality of clinical trials needs to be enhanced and
standardized.
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Background: Falciparum malaria is the most deadly among the
four main types of human malaria. Although great success has
been achieved since the launch of the National Malaria Control
Programme in 1955, malaria remains a serious public health
problem in China. This paper aimed to analyse the geographic
distribution, demographic patterns and time trends of falciparum
malaria in China.
Methods: The annual numbers of falciparum malaria cases dur-
ing 1992-2003 and the individual case reports of each clini-
cal falciparum malaria during 2004-2005 were extracted from
communicable disease information systems in China Center for
